Prospective study on embolization of intracranial aneurysms with the pipeline device (PREMIER study): 3 year results

2022
Written By CCRG CCRG Admin

R Hanel, G Cortez1, D Lopes, P Nelson, A Siddiqui, P Jabbour, V Pereira, I István, O Zaidat, C Bettegowda, G Colby, M Mokin, C Schirmer, F Hellinger, C Given, T Krings, P Taussky, G Toth, J Fraser, M Chen, R Priest, P Kan, D Fiorella, D Frei, B Aagaard-Kienitz, O Diaz, A Malek, C Cawley, A Puri, D Kallmes. Journal of NeuroInterventional Surgery DOI_10.1136/neurintsurg-2022-SNIS.54

Prospective study on embolization of intracranial aneurysms with the pipeline device (PREMIER study): 3-year results with the application of a specific flow-diverter occlusion classification.

Introduction Flow diverters proved to be a safe and efficacious approach for the management of large intracranial lesions. The PREMIER trial was the first prospective study to examine the efficacy of the pipeline embolization device (PED, Medtornic) for the management of small and medium size wide-necked aneurysms. Herein, we present the 3-year follow-up results from the PREMIER cohort.

CCRG CCRG Admin
Previous

Patient aggression in intensive care: A qualitative study of staff experiences
Next

In Vitro Hemocompatibility Evaluation of Modified Rotary Left to Right Ventricular Assist Devices in Pulmonary Flow Conditions